skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat® Soft Mist™ Inhaler: findings from two dose-ranging studies in healthy men

Original Research

(2336) Views  (791) Full article downloads

Authors: Ulrich Feifel, Gudrun Wallenstein, Karl-Ludwig Rominger, Dirk Trommeshauser, Juliane Platz

Published Date October 2008 Volume 2008:3(3) Pages 397 - 403
DOI: http://dx.doi.org/10.2147/COPD.S3744

Ulrich Feifel1, Gudrun Wallenstein1, Karl-Ludwig Rominger1, Dirk Trommeshauser2, Juliane Platz2

1Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Straße 173, 55216 Ingelheim, Germany; 2Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorf Straße 65, 88397 Biberach, Germany

Abstract: Data are presented from two randomized, double-blind, placebo-controlled studies in which the tolerability of tiotropium Respimat® Soft Mist™ Inhaler (SMI), a new-generation, propellant-free device for use in COPD, and the ocular safety of tiotropium were examined. In Study 1, 36 healthy males received tiotropium 8, 16, or 32 µg (n = 9/dose) or placebo (n = 3/dose level), administered once daily via Respimat® SMI for 14 days. Safety and pharmacokinetics were evaluated. In Study 2, 48 healthy males received tiotropium 0.02, 0.04, 0.08, 0.16, 0.28, or 0.40 µg (n = 6/dose) or placebo (n = 2/dose level), applied as two drops to one eye (the highest dose was a significant multiple of a percentage of the proposed Respimat® SMI clinical dose that could be inadvertently deposited in the eye). Ocular parameters were measured over 24 hours. Tiotropium Respimat® SMI at doses up to 32 µg was well tolerated in Study 1; typical dose-dependent anticholinergic adverse events of mild-to-moderate intensity were observed. In Study 2, ocular tiotropium administration did not affect pupil diameter, pupillary reflex, intraocular pressure, or accommodation. Tiotropium Respimat® SMI was well tolerated. Inadvertent ocular exposure to tiotropium up to 0.40 µg is unlikely to result in ocular adverse effects.

Keywords: Respimat® Soft Mist™ Inhaler, tiotropium, anticholinergic, chronic obstructive pulmonary disease






 

Other articles by Dr Sam Phillips



Readers of this article also read:

Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro
Higher lung deposition with Respimat® Soft Mist™ Inhaler than HFA-MDI in COPD patients with poor technique
Pathophysiological roles of microvascular alterations in pulmonary inflammatory diseases: possible implications of tumor necrosis factor-alpha and CXC chemokines
Mechanisms of improvement of respiratory failure in patients with COPD treated with NIV
Preferential recruitment of neutrophils by endothelin-1 in acute lung inflammation induced by lipopolysaccharide or cigarette smoke
Asthma patients prefer Respimat® Soft Mist™ Inhaler to Turbuhaler®
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat® Soft Mist™ Inhaler
Tiotropium HandiHaler® in the treatment of COPD: A safety review
The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
  • Journal Indexing

    See where all the Dove Press journals are indexed

  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio